pancreatic ductal adenocarcinoma, pancreatic cancer pancreatic cancer
Conditions
Interventions
Patients in the intervention arm receive standardized, recurrence-focused follow-up with quarterly blood tests and imaging, unlike patients in the control arm, who are only monitored through medical h
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: -Histologically confirmed macroscopically radical resected (R0-R1) pancreatic adenocarcinoma -Age = 18 years -Written informed consent for being randomized in future studies
Exclusion criteria
Exclusion criteria: -Exclusion criteria for contrast-enhanced CT scan, following the protocol of the department of radiology in eachDPCG affiliated hospital -Mentally or physically incapable of consent -Participation in other DPCG studies with a study-specific follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is overall survival after primary resection of PDAC, designated as the time from the date of surgery untileither death from any cause or last follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives of this study are: •Quality of Life •Compliance to a standardized surveillance strategy •Recurrence-free interval •Clinical and radiological patterns of PDAC recurrence •Prognostic factors for PDAC recurrence •Role of serum tumor marker testing in detecting recurrent PDAC •Eligibility for additional (experimental) treatment at time of recurrence diagnosis •Reasons to abandon treatment for recurrence (i.e. eligibility, deteriorated condition, patient’s wish, doctors’ advice etc.) •Tolerance of additional treatment for recurrent PDAC •Morbidity associated with diagnostic testing •Costs | — |
Countries
Netherlands, United Kingdom
Contacts
Public ContactLA Daamen
Universitair Medisch Centrum Utrecht
Outcome results
None listed